ABIOMED Company Profile (NASDAQ:ABMD)

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED, Inc. (NASDAQ:ABMD) announced its earnings results on Thursday, May, 4th. The company reported $0.33 EPS for the quarter, meeting the Zacks' consensus estimate of $0.33. The firm had revenue of $124.68 million for the quarter, compared to analysts' expectations of $122.82 million. ABIOMED had a net margin of 11.70% and a return on equity of 12.67%. The company's quarterly revenue was up 32.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.24 EPS. View ABIOMED's Earnings History.

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, July, 27th 2017. View Earnings Estimates for ABIOMED.

7 brokerages have issued 12-month price objectives for ABIOMED's stock. Their forecasts range from $140.00 to $170.00. On average, they anticipate ABIOMED's share price to reach $150.00 in the next year. View Analyst Ratings for ABIOMED.

Here are some recent quotes from research analysts about ABIOMED stock:

• 1. According to Zacks Investment Research, "Over the last one month, Abiomed has been trading above the broader Medical Instruments industry. Management expects that robust demand for the Impella product line will continue to drive Abiomed’s top line. The company’s expanding product portfolio will improve penetration into both the prophylactic high-risk PCI and cardiogenic shock patient market. This is evident from the fact that both Impella 2.5 and CP continue to add centers in the U.S. The company also announced the successful launch of the Abiomed Impella Quality Program in fiscal 2017 to improve clinical outcomes. Also, cost-savings efforts remain encouraging. Furthermore, a rising estimate revision trend for the current year indicates a pocket of opportunity for the stock. However, intensifying competition in the niche markets is likely to mar prospects over the long haul." (7/13/2017)
• 2. Jefferies Group LLC analysts commented, "We hosted ABMD management for a series of meetings. As can be expected for a company that is growing revenue 40%+ and for a stock that has increased 33% this year (after 137% last year), the discussions focused on the sustainability of the company’s growth prospects. The outlook remains very encouraging and we offer some observations below. ABMD remains a top pick. ABMD remains at top pick. There are few growth stories that rival ABMD for large, under penetrated markets; established reimbursement; and no appreciable competition. Since the first PMA approval five quarters ago, the company has seen US Impella revenue growth average 49%. The company still only sells about 15k pumps a year in the US despite a market opportunity that is over 200k, a penetration rate of just 7%." (8/9/2016)

Some companies that are related to ABIOMED include ResMed (RMD), Varian Medical Systems (VAR), PerkinElmer (PKI), Bruker Corporation (BRKR), Alere (ALR), Accelerate Diagnostics (AXDX), Natus Medical Incorporated (BABY), Quidel Corporation (QDEL), ABAXIS (ABAX), Mazor Robotics (MZOR), Luminex Corporation (LMNX), GenMark Diagnostics (GNMK), LeMaitre Vascular (LMAT), Accuray Incorporated (ARAY), ViewRay (VRAY), Corindus Vascular Robotics (CVRS), Pacific Biosciences of California (PACB) and Cytosorbents Corp (CTSO).

ABIOMED's management team includes the folowing people:

• Michael R. Minogue, Chairman of the Board, President, Chief Executive Officer
• Michael J. Tomsicek, Chief Financial Officer, Vice President, Treasurer
• David M. Weber, Chief Operating Officer
• William J. Bolt, Senior Vice President, Global Quality, Regulatory and Clinical Operations
• Andrew J. Greenfield, Vice President, General Manager - Global Marketing
• Michael G. Howley, Vice President, General Manager - Global Sales and Marketing
• Dorothy E. Puhy, Lead Independent Director
• Jeannine M. Rivet, Independent Director
• Eric A. Rose M.D., Independent Director
• Martin P. Sutter, Independent Director

ABIOMED's stock is owned by a number of of institutional and retail investors. Top institutional investors include Rockefeller Financial Services Inc. (0.51%), State Treasurer State of Michigan (0.33%), GW&K Investment Management LLC (0.06%), Oregon Public Employees Retirement Fund (0.03%), Aperio Group LLC (0.03%) and Texan Capital Management (0.03%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

ABIOMED's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Rockefeller Financial Services Inc., First Quadrant L P CA, Oakbrook Investments LLC, US Bancorp DE, GW&K Investment Management LLC, Juncture Wealth Strategies LLC and Capital One National Association. Company insiders that have sold ABIOMED stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley and Michael R Minogue. View Insider Buying and Selling for ABIOMED.

ABIOMED's stock was purchased by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan, Handelsbanken Fonder AB, Eqis Capital Management Inc., Fox Run Management L.L.C., CENTRAL TRUST Co, Creative Planning, Sheets Smith Wealth Management and Aperio Group LLC. View Insider Buying and Selling for ABIOMED.

Shares of ABIOMED can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ABIOMED stock can currently be purchased for approximately $144.30.